ReviewAnnual review of genomics and human genetics2010
Patents in genomics and human genetics.
Review in Annual review of genomics and human genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 106 citations in OpenAlex.
- "Unnatural resources?": parallels and distinctions between the Newfoundland Genome and traditional resource sectors.Journal of community genetics · 2024Article
- Trade, intellectual property, and the public health bearing.Health systems (Basingstoke, England) · 2023Article
- Genomics governance: advancing justice, fairness and equity through the lens of the African communitarian ethic of Ubuntu.Medicine, health care, and philosophy · 2021Article
- A survey of direct-to-consumer genotype data, and quality control tool (Computational and structural biotechnology journal · 2021Article
- How should we think about clinical data ownership?Journal of medical ethics · 2020Article
- Access and openness in biotechnology research collaborations between universities and industry.Nature biotechnology · 2019Article
- Big Data and Public-Private Partnerships in Healthcare and Research: The Application of an Ethics Framework for Big Data in Health and Research.Asian bioethics review · 2019Article
- The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project.Journal of the history of biology · 2018Article
- Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance.Annual review of genomics and human genetics · 2017Review
- Eteplirsen in the treatment of Duchenne muscular dystrophy.Drug design, development and therapy · 2017Review
- Myriad's impact on gene patents.Nature biotechnology · 2016Article
- The emerging patent landscape of CRISPR-Cas gene editing technology.Nature biotechnology · 2016Article
- The 2014 Varsity Medical Ethics Debate: should we allow genetic information to be patented?Philosophy, ethics, and humanities in medicine : PEHM · 2015Article
- The translational potential of research on the ethical, legal, and social implications of genomics.Genetics in medicine : official journal of the American College of Medical Genetics · 2015Review
- Trends in genetic patent applications: the commercialization of academic intellectual property.European journal of human genetics : EJHG · 2014Article
- Mobility, retention and productivity of genomics scientists in the United States.Nature biotechnology · 2014Article
- Transparency tools in gene patenting for informing policy and practice.Nature biotechnology · 2013Article
- Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.Current pharmacogenomics and personalized medicine · 2013Article
- Biological diversity in the patent system.PloS one · 2013Article
- Harm, hype and evidence: ELSI research and policy guidance.Genome medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Genomics and human genetics are scientifically fundamental and commercially valuable. These fields grew to prominence in an era of growth in government and nonprofit research funding, and of even greater growth of privately funded research and development in biotechnology and pharmaceuticals. Patents on DNA technologies are a central feature of this story, illustrating how patent law adapts-and sometimes fails to adapt-to emerging genomic technologies. In instrumentation and for therapeutic proteins, patents have largely played their traditional role of inducing investment in engineering and product development, including expensive post-discovery clinical research to prove safety and efficacy. Patents on methods and DNA sequences relevant to clinical genetic testing show less evidence of benefits and more evidence of problems and impediments, largely attributable to university exclusive licensing practices. Whole-genome sequencing will confront uncertainty about infringing granted patents, but jurisprudence trends away from upholding the broadest and potentially most troublesome patent claims.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.